Presented at the 2026 World Conference on Lung Cancer, the phase III PAPILLON and REZILIENT3 trials evaluated first-line combination regimens for advanced non–small-cell lung cancer (NSCLC) driven by EGFR exon 20 insertions. Investigators reported that regimens pairing the antibody amivantamab with the oral agent zipalertinib yielded a statistically significant improvement in progression-free survival compared with the control arms described in the abstract. The cohort results indicated a clinically meaningful delay in disease progression, according to the study team.
Details on exact dosing schedules, individual arm sizes, hazard ratios, confidence intervals, and p-values were not provided in the PubMed abstract. The source did not report granular safety data, specific adverse-event rates, or quality-of-life outcomes for the PAPILLON and REZILIENT3 populations. Those methodological elements appear only in the full-text reports or trial appendices, not in the abstract summary available on PubMed.
The trial authors noted a major interpretive limitation: high rates of post-progression crossover from control therapies to the investigational agents. That crossover, the investigators reported, constrained the ability of the trials to show an overall survival benefit despite the clear progression-free survival advantage. The abstract therefore frames the PFS gain as the primary robust signal from both trials while flagging OS assessment as confounded by treatment switching.
A separate phase III study, HARMONi-2, tested a bispecific antibody, ivonescimab, against standard pembrolizumab in patients with PD-L1-positive advanced NSCLC. The study team reported an overall survival improvement for ivonescimab compared with pembrolizumab in the trial population summarized in the abstract. Based on those results, the authors recommended ivonescimab as a standard-of-care option in China while noting that larger global trials are ongoing to confirm external validity and broader regulatory acceptability.
As with the other reports, the PubMed abstract omitted granular trial statistics: there are no sample-size breakdowns, hazard ratios, median OS values, or formal safety profiles included in the abstract text. The source did not provide the criteria used for PD-L1 positivity, nor the comparator chemotherapy backbones (if any) that might have been used alongside immune therapy in different cohorts. For those operational details, readers must consult the full publications or meeting materials.
Investigators across PAPILLON, REZILIENT3, and HARMONi-2 flagged similar interpretive challenges. High crossover rates, especially in the EGFR exon 20 insertion studies, reduced the ability to detect an overall survival difference despite robust progression-free survival signals. The HARMONi-2 team emphasized that while OS favored ivonescimab in the reported population, global confirmation is required; the abstract specifies that larger multinational studies are underway but does not list their design or timelines.
The source abstract did not discuss long-term follow-up durations, post-progression therapies in detail, or biomarker subanalyses beyond the broad categories of EGFR exon 20 insertions and PD-L1-positive disease. Those omissions limit the capacity to apply these results directly to diverse clinic populations without reviewing the full data sets.
The PubMed summary mentions clinical efficacy end points, but it does not present comprehensive safety and tolerability data for any of the three trials. The abstract did not report specific adverse-event frequencies, grade 3–4 toxicity breakdowns, or drug discontinuation rates. Regulatory action was referenced only indirectly: HARMONi-2 investigators supported ivonescimab as standard of care in China based on the trial's OS data, while the abstract makes no regulatory claims for the amivantamab–zipalertinib combinations.
The abstract leaves several practical questions open. It reports improved progression-free survival for amivantamab–zipalertinib regimens but states that crossover prevented firm overall survival conclusions. It reports an OS advantage for ivonescimab versus pembrolizumab in PD-L1–positive disease and notes that larger global trials are ongoing to validate those findings. The source did not provide detailed methodological parameters, safety tables, or statistical metrics in the abstract, so clinicians and guideline committees must await the full trial publications for complete appraisal.
Limitations explicitly reported in the abstract include the confounding effect of treatment crossover on OS analysis (PAPILLON and REZILIENT3) and the need for broader global data to confirm HARMONi-2 results. Those are the concrete next questions identified by the investigators in the PubMed summary; further trial reports and full-text data releases will be necessary to inform practice-change decisions beyond the contexts stated in the abstract.